• IR-MED announced published, peer-reviewed interim Phase 2 results for its investigational PressureSafe pressure-injury assessment technology.
• Results showed promising agreement with wound-care clinicians’ assessments, with improved diagnostic performance compared with Phase 1.
• No device-related adverse events were identified across either study phase.
• The interim analysis included nine participants; continued enrollment will further evaluate performance across skin tones and anatomical sites.
• Phase 2 enrollment and data collection remain ongoing, with completion expected by March 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IR-MED Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040900PRIMZONEFULLFEED9870035) on November 04, 2026, and is solely responsible for the information contained therein.